Deregulated expression of the oncogenic transcription factor MYC in B‐cell lymphoma induces a vulnerability to disruption of redox homeostasis by pharmacological treatment with the electron transport chain (ETC) complex I inhibitor IACS‐010759 and high‐dose ascorbate. The gene discussed is MYC; the disease is B-cell non-Hodgkin lymphoma.